Mortality from carcinoma of the cervix

Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.

Domestic animal endocrinology·2021

Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.

Domestic animal endocrinology·2020

The role of screening mammography in the era of modern breast cancer treatment.

Climacteric : the journal of the International Menopause Society·2018

The OncoSim model: development and use for better decision-making in Canadian cancer control.

Current oncology (Toronto, Ont.)·2017

Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration.

Current oncology (Toronto, Ont.)·2016

Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

Current oncology (Toronto, Ont.)·2016

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Imbalanced p53-RB signaling triggers cGAS-STING-mediated immune activation in early oral cancer development.

Oncogene·2026

Research advances in the recurrence patterns of glioblastoma.

Biochimica et biophysica acta. Reviews on cancer·2026

IGF2BP3 promotes esophageal squamous cell carcinoma progression by regulating global protein translation.

Biochimica et biophysica acta. Molecular basis of disease·2026

Progress in Hydroxyapatite Nanocarriers for Targeted and Enhanced Osteoporosis Treatment: A Comprehensive Review.

Molecular biotechnology·2026

ATF4 and FGFR4 cooperatively support thyroid cancer progression and CAF-associated tumor-promoting features.

Endocrine·2026

DLL3 serves as a pivotal hub bridging malignant progression and immunosuppression in NECC with therapeutic implications validated via the organoid-TIL co-culture system.

Genes & diseases·2026

Related Experiment Videos

Mortality from carcinoma of the cervix

Related Concept Videos

Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.

Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.

The role of screening mammography in the era of modern breast cancer treatment.

The OncoSim model: development and use for better decision-making in Canadian cancer control.

Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration.

Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Imbalanced p53-RB signaling triggers cGAS-STING-mediated immune activation in early oral cancer development.

Research advances in the recurrence patterns of glioblastoma.

IGF2BP3 promotes esophageal squamous cell carcinoma progression by regulating global protein translation.

Progress in Hydroxyapatite Nanocarriers for Targeted and Enhanced Osteoporosis Treatment: A Comprehensive Review.

ATF4 and FGFR4 cooperatively support thyroid cancer progression and CAF-associated tumor-promoting features.

DLL3 serves as a pivotal hub bridging malignant progression and immunosuppression in NECC with therapeutic implications validated via the organoid-TIL co-culture system.

Related Experiment Videos

Mortality from carcinoma of the cervix

Related Concept Videos

Related Articles